Wednesday, July 8, 2026

pharma · Facioscapulohumeral Muscular Dystrophy (FSHD) · Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) · FULC

Fulcrum Therapeutics

Fulcrum Therapeutics patent portfolio — 11 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

26 Landsdowne St, Cambridge, Massachusetts 02139, US HQ
2016 Founded
73 Employees
Public company Type
FULC · NYSE Ticker
Company details
Intelligence · Patents

Fulcrum Therapeutics patents

11 pharmaceutical patents indexed for Fulcrum Therapeutics. 2 expire within 24 months.

Fulcrum Therapeutics has 11 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 2 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12109198

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11819554

    Compositions and methods for modulating FMR1 expression

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11590111

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11479770

    Use of p38 inhibitors to reduce expression of DUX4

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11291659

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 10973805

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 10537560

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 10342786

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 9051379

    Sp1 polypeptides, modified Sp1 polypeptides and uses thereof

    Expires Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 7253341

    Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof

    Expires Mon Aug 02 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 7183267

    β-lactamase inhibitors and methods of use thereof

    Expires Mon Feb 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Fulcrum Therapeutics have?

11 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Fulcrum Therapeutics patents expire?

2 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.